CHCHD2 mitigates age-associated proteostatic collapse by maintaining homeostasis of the mitochondria-lysosome axis
Acta Neuropathologica · 2026
DOI: 10.1007/s00401-026-03093-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neuropathologica, 2026. Verfasst von Teresa R Kee und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Mitochondria, Lysosomes, Mitochondrial Proteins, Aging. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NIA NIH HHS, Office of Dietary Supplements.
Abstract (Originalsprache)
Mutations in coiled-coil-helix-coiled-coil-helix domain containing 2 (CHCHD2), including the Parkinson’s disease (PD)-linked CHCHD2 T61I mutation, are associated with Lewy body disorders (LBDs) by unknown mechanisms. Here, we demonstrate that CHCHD2 T61I exacerbates age-related brain pathologies, including axonal degeneration and cognitive deficits, by disrupting the mitochondria-lysosome axis. Specifically, CHCHD2 T61I binds and reduces cathepsin B (CTSB) and cathepsin L (CTSL) levels, inducing lysosomal membrane permeability and impairing α-synuclein fibril clearance. We also demonstrate that human CHCHD2 declines in the brain with age, while expression of wild-type CHCHD2 safeguards against age-related neuroinflammation, dopaminergic neuron loss, insoluble protein aggregation, and structural deterioration of mitochondria and lysosomes. These findings, supported by observed reductions in CTSB and CHCHD2 in human LBD brains, establish CHCHD2 as a key regulator of neuronal resilience to aging and proteostatic collapse via the mitochondria-lysosome axis. Preventing age-associated CHCHD2 decline offers a therapeutic strategy to preserve brain health throughout aging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
- Department of Molecular of Medicine, USF Health College of Medicine, Tampa, FL, USA.
- Department of Psychiatry, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
- Institute for Transformative Molecular Medicine, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
- Brain Health Medicines Center, Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
- Geriatric Psychiatry, Geriatric Research Education and Clinical Center, Louis Stokes VA Medical Center, Cleveland, OH, USA.
Förderung
- BLRD VA
- NIA NIH HHS
- Office of Dietary Supplements
- U.S. Department of Defense
- NIH HHS
- U.S. Department of Veterans Affairs
- NIGMS NIH HHS
- NINDS NIH HHS
Zitieren
APA
Kee, T. R., Masters, B. M., Tran, K. D., Jeon, H., Long, M., Xu, G., Khan, S. A., Vázquez-Rosa, E., Sridharan, P. S., Koh, Y., Fujioka, H., Chaput, D., Wang, X., Zhao, X., Pieper, A. A., Kang, D. E., & Woo, J. A. (2026). CHCHD2 mitigates age-associated proteostatic collapse by maintaining homeostasis of the mitochondria-lysosome axis. Acta Neuropathologica. https://doi.org/10.1007/s00401-026-03093-4
Vancouver
Kee TR, Masters BM, Tran KD, Jeon H, Long M, Xu G, et al. CHCHD2 mitigates age-associated proteostatic collapse by maintaining homeostasis of the mitochondria-lysosome axis. Acta Neuropathologica. 2026. doi:10.1007/s00401-026-03093-4
BibTeX
@article{Kee2026,
author = {Kee, Teresa R and Masters, Brianna M and Tran, Khoi D and Jeon, Hanna and Long, Ma and Xu, Grace and Khan, Sophia A and Vázquez-Rosa, Edwin and Sridharan, Preethy S and Koh, Yeojung and Fujioka, Hisashi and Chaput, Dale and Wang, Xinming and Zhao, Xingyu and Pieper, Andrew A and Kang, David E and Woo, Jung-A A},
title = {CHCHD2 mitigates age-associated proteostatic collapse by maintaining homeostasis of the mitochondria-lysosome axis},
journal = {Acta Neuropathologica},
year = {2026},
doi = {10.1007/s00401-026-03093-4}
}
EUVIMED